Scientists have spotted a new variety of riled-up microglia that drives swelling in the human brain. In the November 18 Neuron, researchers from China led by Haixiao Liu, Shunnan Ge, and Yan Qu at ...

L444P KI mice were generated using a loxP replacement vector, resulting in the insertion of a point mutation of leucine to proline (L444P) in exon 10 of the Gba1 gene (Ginns et al., 2014). These Gba1 ...

Affitope AD02 is a synthetic peptide of six amino acids that mimics the N-terminus of Aβ. AFFiRiS hypothesizes that this fragment enables exclusive recognition of Aβ without cross-reacting with APP, ...

This is an active immunotherapy strategy. ACC-001 is a conjugate of multiple short Aβ fragments linked to a carrier made of inactivated diphtheria toxin. Vanutide cridificar is designed to avoid the ...

While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

“[This study] adds to the considerable evidence that the microbiota are involved in the pathogenesis of Parkinson's disease (PD) and other neurodegenerations,” commented Robert Friedland of the ...

Introduction Despite being arguably the second most common dementing disorder, dementia with Lewy bodies, aka DLB, remains both mysterious and understudied. On Tuesday, October 10, 2017, the Lewy Body ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Buoyed by data crediting amyloid removal with ever-so-slightly slowed cognitive decline, many scientists are now optimistic about the prospects for anti-amyloid immunotherapy. Four “-mabs”—of the ...